Common Migraine. Migraine without aura [common migraine]
Conditions
Interventions
Intervention 1: 2.5 mg intravenous halopridol (intervention group). Intervention 2: 5 mg intravenous halopridol (control group).
Treatment - Drugs
2.5 mg intravenous halopridol (intervention group)
5 mg intravenous halopridol (control group)
Sponsors
Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Moderate to severe pain (pain score>4); with History of at least five attacks lasts 4 to 72 hours and headache has at least two of the following characteristics: Unilateral location, Pulsating quality, Moderate to severe pain intensity, Aggravation by or causing avoidance of routine physical activity; At least one of the following during headache: Nausea or vomiting (or both), Photophobia and phonophobia; Not attributable to another disorder Exclusion criteria: First episode of headache; history of allergy to haloperidol; Pregnancy; Breast feeding; Renal failure; Hepatic failure; using other analgesics
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: 0,30, 60, 90 and 120 min after drug administration. Method of measurement: Visual Analog Scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: from starting drug administration to 2 hours after end. Method of measurement: Serial physical exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammad Mehdi Forouzanfar
Shahid Beheshti University of Medical Sciences
Outcome results
None listed